NeOnc Technologies Holdings, Inc. Common Stock (NTHI) Stock Price
NTHIStock
$2.70−74.24%52W
Market Cap$77.77M
P/E—
PEG Ratio—
Div yield—
Beta2.74
NTHI Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-59.81%
Price vs S&P 500 (4W)-17.59%
VGM Score38.38
NTHI Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.17 | -$0.58 | -247.99%(-$0.41) | |
| Q1 2026 | — | -$0.38 | — | |
| Q4 2025 | -$0.37 | -$0.35 | +5.41%(+$0.02) |
NTHI Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
NTHINeOnc Technologies Holdings, Inc. Common Stock | — | — | D | 972.2x | — | — | — | $2.70 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies develops molecular technology for targeted drug delivery to treat central nervous system diseases. The company's lead candidate, NEO100, is in Phase 2a clinical trials for glioblastoma and has received Orphan Drug and Fast Track designations from the FDA.